Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thymoma 1Neoplastic Cells, Circulating 1Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Lobular 1

Interventions

pembrolizumab 25Paclitaxel 20Carboplatin 17Bevacizumab 12Specimen Handling 10Letrozole 10abemaciclib 7dostarlimab 6Taxes 6Blood Specimen Collection 6Medroxyprogesterone Acetate 5Magnetic Resonance Spectroscopy 5Fulvestrant 5Drug Therapy 5Doxorubicin 5Cisplatin 5Biopsy 5olaparib 4lenvatinib 4atezolizumab 4Radiotherapy 4Progestins 4Observation 4Nivolumab 4Megestrol Acetate 4Immunoglobulin G 4Gemcitabine 4trastuzumab deruxtecan 3palbociclib 3X-Rays 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Endometrial Neoplasms × Radiotherapy, Adjuvant × Clear all
NCT05640999 2026-05-12

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Canadian Cancer Trials Group

Phase 2 Recruiting
393 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡